Skip to main content

Advertisement

Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial

Fig. 3

Representative image (a and b) indicating the CD34+ CXCR4+ expression in MNCs by flow cytometry. CD34+ CXCR4+ expression is higher for the saxagliptin group at visit 3 than visit 1 (7.95 and 4.64%, respectively). c Double positivity for CD34 and CXCR4 along the visits for placebo and saxagliptin groups (p < 0.01)

Back to article page